TWD 121.0
(-0.82%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 236.76 Million TWD | 3.03% |
2022 | 229.79 Million TWD | 35.96% |
2021 | 169.01 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 219.71 Million TWD | -7.2% |
2024 Q2 | 335 Million TWD | 52.47% |
2023 Q4 | 236.76 Million TWD | 2.15% |
2023 FY | 236.76 Million TWD | 3.03% |
2023 Q1 | 220.83 Million TWD | -3.9% |
2023 Q2 | 223.88 Million TWD | 1.38% |
2023 Q3 | 231.79 Million TWD | 3.53% |
2022 Q4 | 229.79 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Apex Biotechnology Corp. | 500.07 Million TWD | 52.654% |
Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 91.702% |
Panion & Bf Biotech Inc. | 1.32 Billion TWD | 82.119% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 87.001% |
GenMont Biotech Incorporation | 204.05 Million TWD | -16.028% |
Abnova (Taiwan) Corporation | 69.42 Million TWD | -241.042% |
Adimmune Corporation | 3.7 Billion TWD | 93.613% |
Tanvex BioPharma, Inc. | 1.94 Billion TWD | 87.81% |
Polaris Group | 1.46 Billion TWD | 83.836% |
Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -862.968% |
UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -164.58% |